Skip to main content
Erschienen in: World Journal of Surgery 2/2007

01.02.2007

Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients

verfasst von: Emin Yildirim, MD, Ugur Berberoglu, MD

Erschienen in: World Journal of Surgery | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

We examined the relationship between different expressions of positive axillary lymph nodes (PN) and the outcomes of node-positive breast carcinoma patients to determine the best predictor(s) among these expressions and to assess whether anatomic high level involvement is an independent prognostic factor.

Study Design

In this retrospective study, the primary endpoints were distant recurrence (DR), locoregional recurrences (LRR), and disease-free survival (DFS). Univariate and multivariate prognostic factor analyses were carried out using survival and regression methods in the data of 704 patients with PN.

Results

In multivariate analysis, the number of PN, ratio of PN, log odds of PN, and level III (L-III) involvement, separately, were significant factors for DR in addition to age, tumor size, and lymphovascular invasion (LVI). In the final model including all expressions of nodal involvement, age (continuous P = 0.001; hazard ratio [HR]: 0.98; 95% confidence Interval [95% CI]: 0.96–0.99), tumor size (continuous: P < 0.0001; HR: 1.3; 95% CI, 1.2–1.5), LVI (yes vs. no: P = 0.005; HR: 1.6; 95% CI, 1.2–2.2), and ratio of PN (continuous: P = 0.02; HR: 1.03; 95% CI, 1.01–1.06) were the independent prognostic factors for DR. For LRR, ratio of PN (continuous: P = 0.001; HR: 1.02; 95% CI, 1.01–1.03) was the most important factor in addition to age (continuous: P = 0.02; HR: 0.98; 95% CI, 0.97–0.99) and tumor size (continuous: P = 0.04; HR: 1.3; 95% CI, 1.1–1.6). When patients were stratified by number categories of PN (1–3 vs. 4–9 vs. ≥ 10), there was no difference between DFSs of patients with and without L-III involvement. In contrast, when patients were stratified by L-III involvement, DFSs according to the number categories were statistically different.

Conclusions

Ratio of PN was more valuable than number of PN for predicting outcome in node-positive breast carcinoma patients. Level III involvement was not an independent prognostic indicator either for locoregional or for distant recurrences.
Literatur
2.
Zurück zum Zitat Bembenek A, Schlag PM. Lymph node dissection in breast cancer. Langenbecks Arch Surg 2000;385:236–245PubMedCrossRef Bembenek A, Schlag PM. Lymph node dissection in breast cancer. Langenbecks Arch Surg 2000;385:236–245PubMedCrossRef
3.
Zurück zum Zitat Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998;24:104–109PubMedCrossRef Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998;24:104–109PubMedCrossRef
4.
Zurück zum Zitat Vin-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in breast cancer. Breast Cancer Res 2004;6:R680–R688CrossRef Vin-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in breast cancer. Breast Cancer Res 2004;6:R680–R688CrossRef
5.
Zurück zum Zitat Toma S, Leonessa F, Romanini A, et al. Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res 1991;11:1439–1444PubMed Toma S, Leonessa F, Romanini A, et al. Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res 1991;11:1439–1444PubMed
6.
Zurück zum Zitat Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001;181:313–318PubMedCrossRef Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001;181:313–318PubMedCrossRef
7.
Zurück zum Zitat Barth RJ, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991;126:574–577PubMed Barth RJ, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991;126:574–577PubMed
8.
Zurück zum Zitat Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691–700PubMed Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691–700PubMed
9.
Zurück zum Zitat Luini A, Zurrida S, Galimberti V, et al. Axillary dissection in breast cancer. Crit Rev Oncol Hematol 1999;30:63–70PubMed Luini A, Zurrida S, Galimberti V, et al. Axillary dissection in breast cancer. Crit Rev Oncol Hematol 1999;30:63–70PubMed
10.
Zurück zum Zitat Sinha PS, Thrush S, Bendall S,et al. Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Eur J Cancer 2002;38:1474–1477PubMedCrossRef Sinha PS, Thrush S, Bendall S,et al. Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Eur J Cancer 2002;38:1474–1477PubMedCrossRef
11.
Zurück zum Zitat Voss M, Schneider JW, Apffelstaedt J. Axillary lymph node involvement in stage III breast cancer: treatment implications. J Surg Oncol 1999;71:162–166PubMedCrossRef Voss M, Schneider JW, Apffelstaedt J. Axillary lymph node involvement in stage III breast cancer: treatment implications. J Surg Oncol 1999;71:162–166PubMedCrossRef
12.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al. editors. AJCC Cancer Staging Manuel. 6th ed. Berlin Heidelberg New York: Springer, 2002 Greene FL, Page DL, Fleming ID, et al. editors. AJCC Cancer Staging Manuel. 6th ed. Berlin Heidelberg New York: Springer, 2002
13.
Zurück zum Zitat Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304–306PubMedCrossRef Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304–306PubMedCrossRef
14.
Zurück zum Zitat Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006–2014PubMedCrossRef Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006–2014PubMedCrossRef
15.
Zurück zum Zitat Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481CrossRef Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457–481CrossRef
16.
Zurück zum Zitat Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187–220 Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187–220
17.
Zurück zum Zitat Kleinbaum DG, Kupper LL, Muller KE, et al. editors. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Pacific Grove: Brooks/Cole, 1998 Kleinbaum DG, Kupper LL, Muller KE, et al. editors. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Pacific Grove: Brooks/Cole, 1998
18.
Zurück zum Zitat Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Berlin Heidelberg New York: Springer, 2001 Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Berlin Heidelberg New York: Springer, 2001
19.
20.
Zurück zum Zitat Hanley JA, McNeil BJ. The meaning and use of the area under a receiver characteristic (ROC) curve. Radiology 1982;143:29–36PubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver characteristic (ROC) curve. Radiology 1982;143:29–36PubMed
22.
Zurück zum Zitat Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2–6PubMedCrossRef Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2–6PubMedCrossRef
23.
Zurück zum Zitat Jansen RLH, Hillen HFP, Schouten HC. Prognostic and predictive factors in breast cancer. Netherlands J Med 1997;51:65–77CrossRef Jansen RLH, Hillen HFP, Schouten HC. Prognostic and predictive factors in breast cancer. Netherlands J Med 1997;51:65–77CrossRef
24.
Zurück zum Zitat Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005;91:11–18PubMedCrossRef Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005;91:11–18PubMedCrossRef
25.
Zurück zum Zitat Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Acta Oncol 2000;39:455–466PubMedCrossRef Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Acta Oncol 2000;39:455–466PubMedCrossRef
26.
Zurück zum Zitat Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000;73:134–137PubMedCrossRef Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000;73:134–137PubMedCrossRef
27.
Zurück zum Zitat Recht A. Nodal treatment for patients with early stage breast cancer: guilty or innocent? Radiother Oncol 1992;25:79–82PubMedCrossRef Recht A. Nodal treatment for patients with early stage breast cancer: guilty or innocent? Radiother Oncol 1992;25:79–82PubMedCrossRef
28.
Zurück zum Zitat Yildirim E, Soydinc P, Yildirim N, et al. Role of increased arterial inflow in arm edema after modified radical mastectomy. J Exp Clin Cancer Res 2000;19:427–430PubMed Yildirim E, Soydinc P, Yildirim N, et al. Role of increased arterial inflow in arm edema after modified radical mastectomy. J Exp Clin Cancer Res 2000;19:427–430PubMed
29.
Zurück zum Zitat Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002;72:786–792PubMedCrossRef Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002;72:786–792PubMedCrossRef
30.
Zurück zum Zitat Petrek JA, Heelan MC. Incidence of breast carcinoma related lymphedema. Cancer 1998;83:2776–2781PubMedCrossRef Petrek JA, Heelan MC. Incidence of breast carcinoma related lymphedema. Cancer 1998;83:2776–2781PubMedCrossRef
31.
Zurück zum Zitat Liljegren G, Holmberg L. Arm morbidity after sector resection, axillary dissection with or without postoperative radiotherapy in breast cancer stage I: results from a randomized trial—Uppsala–Orebro Breast Cancer Study Group. Eur J Cancer 1997;33:193–199PubMedCrossRef Liljegren G, Holmberg L. Arm morbidity after sector resection, axillary dissection with or without postoperative radiotherapy in breast cancer stage I: results from a randomized trial—Uppsala–Orebro Breast Cancer Study Group. Eur J Cancer 1997;33:193–199PubMedCrossRef
32.
Zurück zum Zitat Kuehn T, Klas W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients: clinical assessment, significance for life quality and the impact of demographic, oncologic, and therapeutic factors. Breast Cancer Res Treat 2000;64:275–286PubMedCrossRef Kuehn T, Klas W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients: clinical assessment, significance for life quality and the impact of demographic, oncologic, and therapeutic factors. Breast Cancer Res Treat 2000;64:275–286PubMedCrossRef
33.
Zurück zum Zitat Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74:314–317PubMedCrossRef Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74:314–317PubMedCrossRef
34.
Zurück zum Zitat Somner JEA, Dixon JMJ, Thomas JSJ. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 2004;57:845–848PubMedCrossRef Somner JEA, Dixon JMJ, Thomas JSJ. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 2004;57:845–848PubMedCrossRef
35.
36.
Zurück zum Zitat Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).. Eur J Cancer 1992;28A:1415–1418PubMedCrossRef Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG).. Eur J Cancer 1992;28A:1415–1418PubMedCrossRef
37.
Zurück zum Zitat Petrik DW, McCready DR, Sawka CA, Goel V. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol 2003;82:84–90PubMedCrossRef Petrik DW, McCready DR, Sawka CA, Goel V. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol 2003;82:84–90PubMedCrossRef
39.
Zurück zum Zitat Rutgers EJ, EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37:447–453PubMedCrossRef Rutgers EJ, EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37:447–453PubMedCrossRef
40.
Zurück zum Zitat Rutgers EJ. Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 2005;31:568–576PubMedCrossRef Rutgers EJ. Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 2005;31:568–576PubMedCrossRef
41.
Zurück zum Zitat Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140–149PubMedCrossRef Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140–149PubMedCrossRef
42.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817–3827PubMed Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817–3827PubMed
43.
Zurück zum Zitat Goldhirsch A, Glick JH, Gelber RD, et al, and panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–1583PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD, et al, and panel members. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569–1583PubMedCrossRef
44.
Zurück zum Zitat Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569PubMed Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539–1569PubMed
45.
Zurück zum Zitat Kingsmore DB, Ssemwogerere A, Hole DJ, et al. Increased mortality from breast cancer and inadequate axillary treatment. Breast 2003;12:36–41PubMedCrossRef Kingsmore DB, Ssemwogerere A, Hole DJ, et al. Increased mortality from breast cancer and inadequate axillary treatment. Breast 2003;12:36–41PubMedCrossRef
46.
Zurück zum Zitat Gervasoni JE, Taneja C, Chung MA, et al. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000;180:278–283PubMedCrossRef Gervasoni JE, Taneja C, Chung MA, et al. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000;180:278–283PubMedCrossRef
47.
Zurück zum Zitat Pierce LJ. The use of radiotherapy after mastectomy: A review of the literature. J Clin Oncol 2005;23:1706–1717PubMedCrossRef Pierce LJ. The use of radiotherapy after mastectomy: A review of the literature. J Clin Oncol 2005;23:1706–1717PubMedCrossRef
48.
Zurück zum Zitat Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689–1700PubMed Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689–1700PubMed
49.
Zurück zum Zitat Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336–1342PubMed Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336–1342PubMed
50.
Zurück zum Zitat Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early stage breast cancer. An analysis of 259 consecutive patients. Arch Surg 1990;125:1144–1147PubMed Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early stage breast cancer. An analysis of 259 consecutive patients. Arch Surg 1990;125:1144–1147PubMed
51.
Zurück zum Zitat Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869–2878PubMed Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869–2878PubMed
52.
Zurück zum Zitat Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Eng J Med 1997;337:949–955CrossRef Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Eng J Med 1997;337:949–955CrossRef
53.
Zurück zum Zitat Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Eng J Med 1997;337:956–962CrossRef Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Eng J Med 1997;337:956–962CrossRef
54.
Zurück zum Zitat Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high–risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group 82c randomized trial. Lancet 1999;353:1641–1648PubMedCrossRef Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high–risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group 82c randomized trial. Lancet 1999;353:1641–1648PubMedCrossRef
55.
Zurück zum Zitat Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220–1229PubMed Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220–1229PubMed
56.
Zurück zum Zitat Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 2005;97:116–126PubMedCrossRef Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 2005;97:116–126PubMedCrossRef
57.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicine-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 2000;18:2817–2827PubMed Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicine-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 2000;18:2817–2827PubMed
58.
Zurück zum Zitat Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003;237:732–739PubMedCrossRef Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003;237:732–739PubMedCrossRef
59.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233–1241CrossRef Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233–1241CrossRef
60.
Zurück zum Zitat Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217–219PubMed Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217–219PubMed
61.
62.
Zurück zum Zitat Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian metaanalysis. Ann Surg Oncol 1999;61:109–116CrossRef Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian metaanalysis. Ann Surg Oncol 1999;61:109–116CrossRef
63.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–2106
64.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717CrossRef
65.
Zurück zum Zitat Olivotto IA, Truong PT. Postmastectomy radiation therapy: who needs it? J Clin Oncol 2004;22:4237–4239PubMedCrossRef Olivotto IA, Truong PT. Postmastectomy radiation therapy: who needs it? J Clin Oncol 2004;22:4237–4239PubMedCrossRef
66.
Zurück zum Zitat Parmigiani G, Berry DA, Winer EP, et al. Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis. J Clin Oncol 1999;17:1465–1473PubMed Parmigiani G, Berry DA, Winer EP, et al. Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis. J Clin Oncol 1999;17:1465–1473PubMed
67.
Zurück zum Zitat Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608–614PubMedCrossRef Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608–614PubMedCrossRef
68.
Zurück zum Zitat Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow up. J Clin Oncol 2004;22:97–101PubMedCrossRef Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow up. J Clin Oncol 2004;22:97–101PubMedCrossRef
69.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001;50:735–742PubMedCrossRef Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001;50:735–742PubMedCrossRef
70.
Zurück zum Zitat Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol 2003;21:1205–1213PubMedCrossRef Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol 2003;21:1205–1213PubMedCrossRef
71.
Zurück zum Zitat Voogd AC, Nielsen M, Peterse JL, et al., Danish Breast Cancer Cooperative Group, Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688–1697PubMed Voogd AC, Nielsen M, Peterse JL, et al., Danish Breast Cancer Cooperative Group, Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688–1697PubMed
72.
Zurück zum Zitat Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicine-based chemotherapy and postmastectomy implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003;57:336–344PubMedCrossRef Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicine-based chemotherapy and postmastectomy implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003;57:336–344PubMedCrossRef
73.
Zurück zum Zitat Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy. Results of five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol 2004;22:4247–4254PubMedCrossRef Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy. Results of five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol 2004;22:4247–4254PubMedCrossRef
74.
Zurück zum Zitat Jager JJ, Volovics L, Schouten LJ, et al. Locoregional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation. Radiother Oncol 1999;50:267–275PubMedCrossRef Jager JJ, Volovics L, Schouten LJ, et al. Locoregional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation. Radiother Oncol 1999;50:267–275PubMedCrossRef
75.
Zurück zum Zitat Fisher BJ, Perera FE, Cooke AL, et al. Long-term follow-up axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 1997;38:541–550PubMedCrossRef Fisher BJ, Perera FE, Cooke AL, et al. Long-term follow-up axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 1997;38:541–550PubMedCrossRef
76.
Zurück zum Zitat Cheng JCH, Chen CM, Liu MC, et al. Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:980–988PubMedCrossRef Cheng JCH, Chen CM, Liu MC, et al. Locoregional failure of postmastectomy patients with 1–3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:980–988PubMedCrossRef
77.
Zurück zum Zitat Gruber G, Bonetti M, Nasi ML, et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long–term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005;23:7089–7097PubMedCrossRef Gruber G, Bonetti M, Nasi ML, et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long–term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005;23:7089–7097PubMedCrossRef
78.
Zurück zum Zitat Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implication for adjuvant irradiation. Int J Radiat Oncol Biol Phys 2001;50:397–403PubMedCrossRef Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implication for adjuvant irradiation. Int J Radiat Oncol Biol Phys 2001;50:397–403PubMedCrossRef
79.
Zurück zum Zitat Van der Wal BCH, Butzelaar RMJM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481–489PubMedCrossRef Van der Wal BCH, Butzelaar RMJM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481–489PubMedCrossRef
80.
Zurück zum Zitat Voordeckers M, Vinh-Hung V, Van de Sten J, et al. The lymph node ratio as prognostic factor in node positive breast cancer. Radiother Oncol 2004;70:225–230PubMedCrossRef Voordeckers M, Vinh-Hung V, Van de Sten J, et al. The lymph node ratio as prognostic factor in node positive breast cancer. Radiother Oncol 2004;70:225–230PubMedCrossRef
81.
Zurück zum Zitat Haris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989–990CrossRef Haris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989–990CrossRef
82.
Zurück zum Zitat Van der Hage JA, Putter H, Bonnema J, et al., EORTC Breast Cancer Group. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39:2192–2199PubMedCrossRef Van der Hage JA, Putter H, Bonnema J, et al., EORTC Breast Cancer Group. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39:2192–2199PubMedCrossRef
83.
Zurück zum Zitat Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306–312PubMedCrossRef Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306–312PubMedCrossRef
Metadaten
Titel
Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients
verfasst von
Emin Yildirim, MD
Ugur Berberoglu, MD
Publikationsdatum
01.02.2007
Erschienen in
World Journal of Surgery / Ausgabe 2/2007
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-006-0487-5

Weitere Artikel der Ausgabe 2/2007

World Journal of Surgery 2/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.